Pediatric Radiology

, Volume 45, Issue 1, pp 81–85 | Cite as

Selective CT for PET/CT: dose reduction in Langerhans cell histiocytosis

  • Michael J. GelfandEmail author
  • Susan E. Sharp
  • Joseph S. Palumbo
Original Article



In Langerhans cell histiocytosis (LCH), FDG PET demonstrates active disease in bone. Other imaging modalities show the effects of bone destruction by LCH.


To evaluate a selective CT method for reducing effective dose from FDG PET/CT in LCH, using whole-body modified attenuation correction CT at extremely low exposure settings, with repeat selective limited-volume CT at typical localization settings.

Materials and methods

Fifty-one PET/CT scans were performed in 23 LCH patients, median patient age 8.5 years (range: 1–25 years). Thirty-four were performed with modified attenuation correction CT settings, with bed positions (excluding head and neck) repeated at localization CT settings in regions with abnormal or difficult to interpret PET findings.


Of 34 modified attenuation correction PET/CT scans, 10 required repeat localization CT of 1 to 3 bed positions (total: 17 bed positions). Lytic bone lesions were easily recognized at modified attenuation correction settings. Calculated average effective dose for the 34 whole-body CT scans at modified attenuation correction settings was 1.65 mSv. Average effective dose per patient for repeat imaging of 17 bed positions at localization settings was 1.19 mSv. Average total effective dose from CT for all 34 scans performed at the modified attenuation correction CT settings, including the 10 repeat localization CT scans, was 2.0 mSv. High-quality PET scans were consistently obtained with reduced FDG-administered activities of 3.7 MBq/kg (0.10 mCi/kg). In active LCH, abnormal FDG uptake was seen in all lytic bone lesions ≥9 mm, including cranial vault lesions.


Substantial reduction in effective dose is possible using selective CT techniques for FDG PET/CT.


Langerhans cell histiocytosis PET/CT [F-18]2-fluoro-2-deoxyglucose (FDG) Dose reduction Children 


Conflicts of interest



  1. 1.
    Anton CG (2012) Langerhans cell histiocytosis. In: Donnelly LF, Jones CG, O’Hara SM, Anton CG et al (eds) Diagnostic imaging: pediatrics, vol 6, 2nd edn. Amirsys, Salt Lake City, pp 120–123Google Scholar
  2. 2.
    Binkovitz LA, Olshefski RS, Adler BH (2003) Coincidence FDG-PET in the evaluation of Langerhans’ cell histiocytosis: preliminary findings. Pediatr Radiol 33:598–602PubMedCrossRefGoogle Scholar
  3. 3.
    Kaste SC, Rodriguez-Galindo C, McCarville ME et al (2007) PET-CT in pediatric Langerhans cell histiocytosis. Pediatr Radiol 37:615–622PubMedCrossRefGoogle Scholar
  4. 4.
    Phillips M, Allen C, Gerson P et al (2009) Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer 52:97–101PubMedCrossRefGoogle Scholar
  5. 5.
    The French Langerhans’ Cell Histiocytosis Study Group (1996) A multicentre retrospective survey of Langerhans’ cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child 75:17–24CrossRefGoogle Scholar
  6. 6.
    Bernstrand C, Sandstedt B, Ahström L et al (2005) Long-term follow-up of Langerhans cell histiocytosis: 39 years’ experience at a single centre. Acta Paediatr 94:1073–1084PubMedCrossRefGoogle Scholar
  7. 7.
    Fahey FH, Palmer MR, Strauss KJ et al (2007) Dosimetry and adequacy of CT-based attenuation correction for pediatric PET: phantom study. Radiology 243:96–104, Erratum in: Radiology 2008 248:1085PubMedCrossRefGoogle Scholar
  8. 8.
    Stabin MG, Gelfand MJ (1998) Dosimetry of pediatric nuclear medicine procedures. Q J Nucl Med 42:93–112PubMedGoogle Scholar
  9. 9.
    ImPACT Software. London, UK. Accessed 3 June 2014
  10. 10.
    Alessio AM, Kinahan PE, Manchanda V et al (2009) Weight-based, low-dose pediatric whole-body PET/CT protocols. J Nucl Med 50:1570–1577PubMedCrossRefGoogle Scholar
  11. 11.
    Lee HJ, Ahn BC, Lee SW et al (2012) The usefulness of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with Langerhans cell histiocytosis. Ann Nucl Med 26:730–737PubMedCrossRefGoogle Scholar
  12. 12.
    Mueller WP, Melzer HI, Schmid I et al (2013) The diagnostic value of 18F-FDG PET and MRI in paediatric histiocytosis. Eur J Nucl Med Mol Imaging 40:356–363PubMedCrossRefGoogle Scholar
  13. 13.
    Gelfand MJ, Parisi MT, Treves ST (2010) Pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines. J Nucl Med 52:318–322CrossRefGoogle Scholar
  14. 14.
    Gelfand M, Huang J, Sharp S (2011) PET with selective CT at follow-up in pediatric and adolescent patients with lymphoma (abstract). Pediatr Radiol 41:S270–S271CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Michael J. Gelfand
    • 1
    Email author
  • Susan E. Sharp
    • 1
  • Joseph S. Palumbo
    • 2
  1. 1.Section of Nuclear Medicine, Department of RadiologyCincinnati Children’s Hospital Medical CenterCincinnatiUSA
  2. 2.Cancer and Blood Diseases Institute, Department of PediatricsCincinnati Children’s Hospital Medical CenterCincinnatiUSA

Personalised recommendations